Canaccord analyst William Plovanic raised the firm’s price target on Edwards Lifesciences (EW) to $75 from $71. The firm said Edwards delivered an in-line revenue quarter with management largely reiterating guidance, highlighted by continued belief that TAVR could reaccelerate with an indication expansion and TMTT will keep growing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Hold Rating on Edwards Lifesciences: Balancing Positive Trends with TAVR Uncertainties
- Texas Instruments, Mondelez downgraded: Wall Street’s top analyst calls
- Edwards Lifesciences price target raised to $75 from $72 at Baird
- Edwards Lifesciences upgraded to Overweight from Neutral at Piper Sandler
- Edwards Lifesciences Reports Strong Q1 Growth